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Abstract
Background: Prostate cancer is the second leading cause of cancer death among men. Multiple evidence suggests
that a population of tumor-initiating, or cancer stem cells (CSCs) is responsible for cancer development and
exceptional drug resistance, representing a highly important therapeutic target. The present study evaluated CSC-
specific alterations induced by new-generation taxoid SBT-1214 and a novel polyenolic zinc-binding curcuminoid,
CMC2.24, in prostate CSCs.
Principal Findings: The CD133high/CD44high phenotype was isolated from spontaneously immortalized patient-
derived PPT2 cells and highly metastatic PC3MM2 cells. Weekly treatment of the NOD/SCID mice bearing PPT2-
and PC3MM3-induced tumors with the SBT-1214 led to dramatic suppression of tumor growth. Four of six PPT2 and
3 of 6 PC3MM2 tumors have shown the absence of viable cells in residual tumors. In vitro, SBT-1214 (100nM-1µM;
for 72 hr) induced about 60% cell death in CD133high/CD44+/high cells cultured on collagen I in stem cell medium (in
contrast, the same doses of paclitaxel increased proliferation of these cells). The cytotoxic effects were increased
when SBT-1214 was combined with the CMC2.24. A stem cell-specific PCR array assay revealed that this drug
combination mediated massive inhibition of multiple constitutively up-regulated stem cell-related genes, including key
pluripotency transcription factors. Importantly, this drug combination induced expression of p21 and p53, which were
absent in CD133high/CD44high cells. Viable cells that survived this treatment regimen were no longer able to induce
secondary spheroids, exhibited significant morphological abnormalities and died in 2-5 days.
Conclusions: We report here that the SBT-1214 alone, or in combination with CMC2.24, possesses significant
activity against prostate CD133high/CD44+/high tumor-initiating cells. This drug combination efficiently inhibits
expression of the majority of stem cell-related genes and pluripotency transcription factors. In addition, it induces a
previously absent expression of p21 and p53 (“gene wake-up”), which can potentially reverse drug resistance by
increasing sensitivity to anti-cancer drugs.
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Introduction
Prostate cancer (PrC) is the second leading cause of cancer
death among men in Western society [1]. It is initially sensitive
to androgen deprivation therapy, but more than 70% of patients
will face post-treatment recurrence and transition of the
disease to an incurable state [2]. For patients diagnosed with
androgen-independent PrC, microtubule stabilizers such as
Paclitaxel (Ptx; Taxol) are a first-line treatment strategy that is
initially effective. However, approaches to treating
chemoresistant PrC are currently lacking [3]. After the initial
discovery of cancer stem cells, CSCs [4], it became
increasingly evident that tumors are organized hierarchically,
containing a relatively minor (but varying) population of tumor-
initiating cells and a heterogeneous majority of bulk tumor cells
at different stages of maturation. In support of the CSC concept
of carcinogenesis, a recent study demonstrated that the
expression of several commonly used CSC markers, i.e. CD44,
CD166 and ALDH-1, as well as the proportion of cells that
express these markers, increases with aging [5]. It is an
established phenomenon that aging correlates with a sharp
increase in the incidence of prostate and many other cancers
[1]. Accumulated knowledge clearly indicates that CSCs are
responsible for tumor development, maintenance and
resistance to standard treatment modalities. Thus, it has been
shown for many cancer types that the tumorigenic cells
expressing common CSC markers, in particular CD133 and
CD44, are exceptionally resistant to conventional anti-cancer
drugs (such as 5-FU, oxaliplatin, irinotecan, docetaxel and
others). Moreover, the number of such cells can be significantly
propagated after therapy [6-13], which usually manifests as
more drug-resistant and more aggressive recurrent and
metastatic disease. Therefore, it is conceivable that CSCs
represent the most crucial target in the development of a new
generation of anti-cancer drugs.
Preclinical evaluation of the candidate anti-cancer agents is
traditionally based on the use of monolayer cultures of the total,
unselected cancer cells. However, this in vitro model ignores
rare yet functionally significant, highly drug-resistant tumor-
initiating cells, and thereby has low relevance to the complexity
and pathophysiology of in vivo tumor tissues. In addition, it was
recently demonstrated that the most commonly used
established cancer cell lines have no correlation with original
clinical samples, which can lead to critical misevaluation of
drug efficacy [14]. This can partly explain the high rate of
attrition of candidate anti-cancer agents. Thus, only 5% of
agents that have anticancer activity in preclinical development
are licensed [15]. Therefore, the identification and
characterization of patient-derived CSCs, the development of
optimal in vivo and in vitro preclinical models, and CSC-
targeted analyses of the drug-induced alterations represent
critical steps in the assessment of novel anti-cancer drugs.
However, it is notoriously difficult to establish primary cell lines
from prostate carcinomas, and this field remains to be one of
the most controversial topics in cancer research [16]. First of
all, PrC is a malignancy with a high degree of cellular and
molecular heterogeneity, therefore, there are objective
difficulties in the isolation of pure cell populations from prostate
tissues. At the molecular level, there are currently no definitive
markers to prove the malignant or nonmalignant nature of
prostate cells, and to distinguish between normal and cancer
stem cells. Growing evidence also suggests that CSCs might
represent a heterogeneous subpopulation of the tumor-
initiating cells [17-23]. Nevertheless, a combination of multiple
cell surface markers for initial cell sorting followed by thorough
functional characterization of the isolated cell phenotypes can
lead to the identification of the most functionally significant (i.e.
tumor- and metastasis-initiating, or the most drug-resistant) cell
populations.
In our previous studies, we have found that a new-generation
taxoid, SBT-1214, induces effective long-term suppression of
colon tumor xenografts [24] and dramatically down-regulates
the expression of multiple stem cell-relevant genes [25].
Searching for safe agents that can potentially decrease
systemic toxicity and further improve the CSC-targeted
activities of the SBT-1214, we were motivated by numerous
anti-cancer features of the natural phytochemical curcumin
(diferuloylmethane). In a large number of studies, curcumin has
been reported to amplify the cytotoxic effects induced by
diverse chemotherapeutic drugs and, importantly, to inhibit
clonogenic capacity and induce pro-apoptotic effects on drug-
resistant cells expressing stem cell markers [26]. In particular,
curcumin significantly decreases the proliferative potential and
increases apoptosis of both androgen-dependent and
androgen-independent prostate cancer cell lines [27,28].
However, curcumin has low bioactivity and bioavailability,
which stimulated us to develop about 30 structural analogues
of curcumin (polyenolic zink-binding agents; PEZBINs),
including the current lead compound, CMC2.24, which has
higher bioactivity, better solubility and no evidence of toxicity
even at high doses [29]. The goal of this study was to test the
efficacy of the SBT-1214 as a single agent, and its combination
with this novel curcuminoid against primary and metastatic
prostate tumor-initiating cells.
Results
Establishment and characterization of the
spontaneously immortalized primary prostate cancer
cell line, PPT2
Dissociated cells of needle biopsies from 22 resected
prostate carcinomas of various histological grades were tested
for clonogenic and tumorigenic potential in vivo and in vitro as
described in the Methods section. Twenty specimens contained
a subpopulation of the fast-adherent cells (FA) to the type I
collagen, which initially proliferated in serum-free stem cell
medium. Fourteen of the 22 specimens induced floating
multicellular aggregates, and only three specimens were able
to induce dense 3D spheroids characteristic of CSCs.
However, the majority of the primary cells lost their clonogenic
and sphere-forming capacities after several passages, which is
in line with numerous observations that primary prostate cancer
cells have a finite lifespan (5-6 passages) [16]. In contrast,
tumor cells isolated from the patient with stage pT2c pNX pMX
PrC were spontaneously immortalized and continued long-term
in vitro and in vivo growth (˃28 passages, currently). With serial
Prostate CSCs Inhibition with SBT-1214/CMC2.24
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rounds of transplantation and passaging in a stem cell medium,
three different cell populations became evident: the major
population of elongated cells, numerous round holoclones
containing small cells, and rare, very large multinuclear cells
(which we often observe in several established and primary
prostate and colon cancer cell lines). Subcloning of these
small-cell-containing holoclones led to dramatic enrichment of
cells expressing high levels of CD133, CD44, CD44v6,
EpCAM, CD49f and CD166 (Figure 1A). This cell line (called
PPT2) was serially propagated as NOD/SCID mice tumor
xenografts, floating 3D spheroids and type I collagen-adherent
cultures. According to the ATCC report (ID number 002872),
the PPT2 cells are unique human cells with no match to any
profile in the ATCC STR database, which means that they are
not contaminated with any known established cell lines.
Although phenotype of the CSC-enriched cultures is dynamic
due to the dual nature of the CSCs (i.e., ability to self-renew
and to generate committed progenitors), the PPT2 cells retain
relatively stable phenotypes even up to 8 weeks after the last
MACS-CD133+ cell sorting and culturing on type I collagen-
coated surfaces in serum-free Mesenchymal Stem Cell Growth
medium, MSCGM (Lonza; Table 1; Figure 1). Thus, virtually
the entire population of PPT2 cells was undifferentiated (only
3-5% expressed marker of differentiated cells, pan-keratin),
positive for EpCAM, CD49f, standard isoform of the CD44
(98-99%; clone MEM-85; Invitrogen), and up to 72% express
variant isoform, CD44v6 (clone 2F10; R&D). After ˃ 27
passages, about 90% of PPT2 cells still express moderate-to-
high levels of CD133 and possess very high sphere-forming
capacity in 3D culture containing 1:4 collagen type I/ Stemline
Pluripotent Culture Medium (SPCM; Sigma-Aldrich). Twelve-
sixteen percent of the PPT2 cells were positive for androgen
receptor (AR+), and 8-10% were positive for CXCR4 (Figure
1A). In contrast to the original tumor tissue, purified CD133+
cells did not express PSA, which appeared again in the NOD/
SCID mice tumors after transplantation of the CD133+ cells
(Figure 1B). The vast majority of the CD133+ PPT2 cells
expressed high cytoplasmic levels of vimentin and nestin,
characteristic of neural and embryonic stem cells. The
expression of these two markers was highest in gigantic
multinucleated cells (MNCs; Figure 1C). Both nuclear and
cytoplasmic fractions of the PPT2 cells expressed c-Myc,
whereas other pluripotency markers (Oct-4 and Sox-2) were
detected only in nuclear fraction (Figure 1D). Importantly, PPT2
cells were negative for pro-apoptotic/tumor suppressor
proteins, p53 and p21, and extremely resistant to standard anti-
cancer drugs. By present time, after about 2.5 year of
maintenance, the vast majority of the PPT2 cells remains at an
immature state, continues to express high ratios and high
levels of commonly used stemness and pluripotency markers
mentioned above and retains very high tumor-initiating,
clonogenic and sphere-forming capacities during serial
transplantations of the relatively low cell numbers. All of the
above motivated our team to test the two proprietary drugs,
SBT-1214 and CMC2.24 against this highly drug resistant,
CSC-enriched primary prostate cancer cell line and for
comparison, against established a highly metastatic derivative
of the PC-3 cell line, PC3MM2 cells, which were characterized
in our previous study [30].
Cytotoxic effects of SBT-1214 against CSC-enriched
prostate cancer cells in vitro
Treatment with SBT-1214 and, for comparison, with the
commonly used microtubule stabilizing agent paclitaxel (Ptx;
Taxol) increased the ratios of cells with highest expression of
CD133 in a concentration-dependent manner (from 10nM to
10µM; for 24 hours) in both PPT2 and PC3MM2 cell lines
(representative FACS is shown on Figure 2A, B). This data
suggests that both drugs preferentially affected cells with low
CD133 expression, and initially did not affect or even stimulate
proliferation of the CD133high cells. However, a longer treatment
(for 48-72 hours) revealed a profound difference between the
cytotoxic effects of SBT-1214 and Ptx: while Ptx-treated cells
retained viability and the number of viable cells was still
increased, up to 60% of the SBT-1214-treated CD133+ cells
were killed with the same concentrations of the drug (the MTT
assay data are shown on Figure 2C, D; Figure 3A).
Surprisingly, lower concentrations of SBT-1214 (100nM-1μM)
induced higher cytotoxicity in PPT2 cells compared to 10µM
drug concentration. Paclitaxel at 10 µM was cytotoxic and
induced about 40% cell death (Figure 2C, D). At this time point,
an increased ratio of very large MNCs (often ≥200 µm) was
obvious in both PPT2 and PC3MM2 cells (Figure 3A, B). To
test whether or not treatment with SBT-1214 affects the
clonogenic potential of the CD133+ cells, PPT2 and PC3MM2
floating spheroids were treated with 1µM of the drug for 24
hours in order to induce alterations, but avoid profound cell
death. We have found that in contrast to control untreated
spheroids, SBT-1214 treated cells lost their ability to induce
both secondary 3D spheroids (Figure 3C) or collagen-adherent
colonies (not shown). Both PPT2 and PC3MM2 cells-
treatment-survivors exerted profound cell death at 2-5 days
post-treatment with SBT-1214 (Figure 3D).
In vivo efficacy of SBT-1214 against prostate tumor
xenografts induced by CD133+ cell populations
After transplantation of the CD133+ PPT2 and PC3MM2
cells, NOD/SCID mice were randomly divided into 3 groups for
each cell type: one as an untreated control (n=4), a second
group for SBT-1214 treatment with 40, 40, 40 mg/kg weekly
regimen (n=4), and a third group for treatment with 40, 20, 20,
20 mg/kg weekly regimen (n=6). Treatment was started 2-3
weeks after transplantation of the tumor cells, when tumor
xenografts reached ˃100 mm3; tumor development was
monitored weekly. Although all four tumors treated with 40, 40,
40 mg/kg weekly regimen had dramatically shrunk by the third
treatment, all mice expressed common signs of systemic
toxicity and were euthanized (data are not shown). The
treatment with 40, 20, 20, 20 mg/kg weekly regimen induced
more significant tumor regression (Figure 4A-D), with much
lower systemic toxicity. One week after the last treatment, all
residual tumors were harvested and analyzed
histopathologically and for ex vivo clonogenic capacity.
Untreated control tumors were removed upon reaching ~2 cm
in largest diameter in accordance with the IRB requirements.
Prostate CSCs Inhibition with SBT-1214/CMC2.24
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Histopathological analysis.  The hematoxylin and eosin
stained tissue sections of the control untreated patient-derived
CD133+ cell-induced NOD/SCID mice tumor xenografts
showed highly atypical epithelial cells forming nests and gland-
like structures, consistent with poorly differentiated
adenocarcinoma (Figure 4E). Numerous atypical mitotic figures
and central necrosis were usually present. The two larger
PPT2-induced SBT-1214-treated residual tumors were also
diagnostic of poorly differentiated adenocarcinoma, but
possessed a greater degree of nuclear atypia, and only few
mitotic figures. In addition, the SB-1214-treated tumor showed
focal hyalinization but no evidence of necrosis. Smaller residual
tumors (n=4) showed a higher level of hyalinization and a lack
of viable cells.
Post-treatment alterations in clonogenic and sphere-
forming capacities.  Total cell suspensions from the control
and SBT-1214-treated residual tumors were seeded on type I
collagen-coated dishes and ULA plates to test for the presence
of CSCs and their ability to induce secondary spheroids or
adherent cell colonies. Four of six PPT2-induced and three of
six PC3MM2-induced SBT-1214 treated residual tumors were
composed of tan or dark red masses which did not show the
presence of viable cells, and did not produce either adherent or
floating colonies in culture. Two of the PPT2-induced post-
treated residual tumors and three of the PC3MM2-induced
tumors contained viable slowly proliferating cells. The two
PPT2 residual tumors also showed clusters of gigantic
multinucleated cells-treatment-survivors (arrows on Figure 4F)
similar to those commonly observed after treatment of the
CSC-enriched populations with chemotherapeutic agents in
vitro (Figure 3B). However, these cells did not induce any
compact spheroids in non-adherent culture conditions,
Figure 1.  Molecular characterization of the primary prostate PPT2 cell line.  (A) Representative FACS analyses of the different
cell surface markers expression in unsorted PPT2 cells grown for 4 weeks on type I collagen in MSGB medium. Each dotted square
represents the population of cells expressing moderate/high levels of a particular marker conjugated with different fluorescent tags.
Note a long-term retention of the CD133-APC, standard (CD44-PE) and variant (CD44v6-FITC) CD44 and CD49f-APC. In contrast,
only small fractions of the PPT2 cells expressed a marker of basal cells, p63, a marker of differentiated cells, pan-keratin, CK18, AR
and CXCR4. (B) Immunohistochemical analysis shows that, in contrast to parental tumor tissue, purified CD133+ PPT2 cells do not
express PSA in vitro; however, PPT2-induced NOD/SCID tumor xenografts are weakly PSA-positive. (C) Immunocytochemical
analysis shows uniform expression of vimentin and nestin, with especially high levels of these markers of neural stem cells in large
MNCs. (D) Western blot analysis shows expression of the pluripotency markers in nuclear and cytoplasmic fractions of the CD133+
PPT2 cells. Both the nuclear and cytoplasmic fractions expressed c-Myc and were negative for p53 and p21; only the nuclear
fraction expressed Oct-4 and Sox-2.
doi: 10.1371/journal.pone.0069884.g001
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producing only loose multicellular aggregates, which underwent
profound cell death in several days of ex vivo culturing (Figure
4G). In contrast, dissociated cells from untreated tumor
xenografts were serially passaged in vivo and in vitro (Figure
4H shows type I collagen-adherent holoclone and floating
spheroids induced during serial passaging of the untreated
PPT2 mice tumor xenograft cells).
Combination of SBT-1214 with CMC2.24 increases its
CSC-targeted cytotoxic and stem cell-modulating
activities
To study the potential interactions between SBT-1214 and
Ptx with a novel synthetic curcuminoid, CMC2.24, the
effectiveness of various drug concentrations and their
combination with CMC2.24 was evaluated in the tumor-
initiating fractions of the PPT2 and PC3MM2 cell lines. Cell
viability was determined by the MTT assay and FACS analysis.
We have found that the CMC2.24 (as well as curcumin; not
shown) often exerted biphasic effects on prostate CD133+ cells.
Thus, treatment with low concentrations of CMC (up to 10µM)
for 72 hr stimulated cell proliferation, whereas higher doses
(10-40µM) were increasingly cytotoxic (Figure 5A, B). FACS
analysis revealed that in contrast to SBT-1214 and Ptx,
CMC2.24 did not induce an increase in the ratios of cells with
highest expression of CD133 (Figure 5C; black dotted area),
but led to a significant shift of the entire cell population toward
differentiation (C; area with red asterisk) and some increase in
cells with highest expression of pan-keratin (C; red dotted
Table 1. Phenotypic profiling of the PPT2 and PC3MM2
cells with FACS analysis*.
 PPT2 cells** PC3MM2 cells***
Marker Source Expr. level % of cells Expr. level % of cells
CD133 Miltenyi Bio. +++ 75±15 ++/+++ 3±1
CD44 Invitrogen MEM-85 +++ 99.5±0.5 ++/+++ 7.5±2.5
CD44v6 R&D Clone 2F10 +++ 56±16   
CD49f BioLegends +++ 99.5±0.5 +++ 94±2
CD166 BD Biosci. +++ 99.3±0.5 ++/+++ 86±8
EpCAM Miltenyi Bio. +++ 98±0.5 ++/+++ 83±5
Pan-Kerat Cell Signal. ++ 4±1   
CK5 Santa Cruz + 7±1 + 3±1
CK18 Santa Cruz + 5.5±2.5 + 3.5±0.5
CK5/CK18 Santa Cruz + 4.5±0.5 + 2.5±0.5
p63 Santa Cruz + 5±2.5 + 7±1
AR Santa Cruz + 14±2 ++/+++ 5±2
CXCR4 R&D ++ 10.5±1 +++ 12±2
* Mean percentage of cells expressing particular cell surface marker was
calculated based on the three independent FACS analyses.
** PPT2 cells (unsorted before analysis, but established by previous repeated
MACS-CD133+ cell sorting) were cultured on type I collagen-coated dishes in
MSCB medium for 2, 4 and 8 weeks.
*** Unsorted PC3MM2 cells were cultured on type I collagen-coated dishes in
MSCB medium for 1-2 weeks.
+ ++ and +++ represents low, moderate and high expression.
doi: 10.1371/journal.pone.0069884.t001
area). These data indicate that low concentrations of CMC2.24
increase proliferation of the non-stem progenitors rather than
CSCs. Importantly, the combination of 30µM CMC2.24 (which
is not toxic even at much higher doses [29]) with low
concentrations of SBT-1214 or Ptx (10nM-1µM) exerted more
profound death of the CD133+ cells than each compound as a
single agent (Figure 5D, E). After temporary post-treatment
accumulation of the large multinucleated cells, they lost the
ability to induce floating 3D spheroids and underwent profound
cell death similarly to the SBT-1214-treated cells shown on
Figure 3.
SBT-1214-induced alterations in the stemness-related
gene expression profile
In our previous studies, using genome-wide and pathway-
specific gene expression profiling, we have found that the
tumorigenic cell populations isolated from the established
prostate and colon cancer cell lines expressed upregulated
levels of the anti-apoptotic genes, ABC transporters and the
majority of stem cell-related genes [25,30,31]. Our proteomics
study carried out in collaboration with Harvard Proteomics
Resource on the CSC-enriched versus differentiated PC3MM2
cells revealed 198 differentially expressed proteins out of 600
analyzed ones (unpublished data). Among them were many
proteins involved in stem cell function, cell motility, invasion,
metastasis and poor prognosis, including vimentin, nestin,
S100, heat shock proteins HS90A and HS90B, moesin,
galectin and many others. To determine possible drug-induced
alterations in stemness gene expression, we analyzed CD133+
PPT2 cells before and after treatment with the SBT-1214/CMC
2.24 combination. Using PCR array assay (PAHS 501;
SABiosciences) with filtering criteria of a 1.5- or greater- fold
change in expression, we have found that about 50% of the
analyzed 84 stem cell-related transcription factors (TFs) were
upregulated in CD133+ versus differentiated PrC cells (Figure
6A). Among them were CDX2, DLX2, DNMT3B, EGR, FOXP3,
GLI2, HOX family TFs, IRX4, JUN, KLF2, NFATC1, NR2F2,
PCNA, PITX3, POU4F1, SIX2, SOX2, SOX9, TERT, WT1 and
others. Single treatment with SB-1214 (1µM) and CMC2.24
(10µM) for 24 hours induced significant down-regulation of
these over-expressed genes (Figure 6B). Western blot analysis
has shown that SBT-1214 and CMC2.24 as single agents
induced moderate down-regulation of c-Myc and Sox2 in
nuclear extracts of both CD133+ and bulk PPT2 cells, whereas
combined drug administration led to practically complete
inhibition of their expression (Figure 6C). Importantly, nuclear
fractions of both CD133+ and bulk PPT2 cells did not express
the two tumor suppressors/regulators of apoptosis, p53 and
p21 (Figure 7A), which partially can explain their extreme
resistance to anti-cancer drugs. Both SBT-1214 and CMC2.24,
and especially their combination induced expression of p21
and p53. Such “gene wake-up” induced by pretreatment with
the drug combination (SB-1214; 1µM and CMC2.24; 10µM) for
24 hours dramatically increased further sensitivity of these
highly drug-resistant cells to the second treatment, leading to
virtually complete death of the CSC-enriched cells (Figure 7B,
C).
Prostate CSCs Inhibition with SBT-1214/CMC2.24
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Discussion
Accumulated data suggest that the tumor-initiating cells,
CSCs, are not only highly resistant to conventional therapeutic
strategies, but may actually promote cancer progression due to
the drug-induced compensatory increase in their self-renewal
[6-13]. Therefore, the search for effective therapeutic
interventions should be based on the evaluation of the post-
treatment status of the tumor-initiating CSCs, and not only on
tumor shrinkage. In our studies, a high combined expression of
CD133 and CD44 was selected as the first criterion for the
isolation and initial enrichment of prostate CSCs. However, it is
important to mention that further stringent stem cell-promoting
culturing conditions are necessary for the maintenance and
propagation of prostate CSCs. Such conditions include growing
on type I collagen-coated surface or in 3D type I collagen-
containing culture, in stem cell serum-free medium, at low cell
density and with repeated sets of cell sorting. The stemness
features of cells grown under these conditions were
demonstrated in our previous functional and genomics studies
[25,30-32]. In particular, we have found the overactivation of
several developmental cascades, such as Hedgehog, EGFR,
Wnt/β-catenin and Notch, which was linked with prostate stem
cell regulation [33-35] and the progression of prostate cancer to
androgen-independence and metastasis [36,37].
Currently, consensus does not exist regarding the phenotype
of functionally distinctive subpopulations of normal versus
cancerous cells in general, and normal stem cells versus CSCs
in particular. However, accumulated data suggest that tumor-
initiating cells can represent a heterogeneous population. It
was shown recently that Epcam + /CD44+ and Epcam + /CD44+/
CD49fhigh basal cells can form abundant PrC spheres; in
contrast, Epcam + /CD44− cells cannot form spheres, but
possess the Epcam + /CD44−/CD49fhigh subpopulation with a
basal profile similar to Epcam + /CD44+/CD49fhigh sphere-
forming cells, which are p63 + /AR low/PSA− [23]. After >10
Figure 2.  In vitro cytotoxicity of SBT-1214 and paclitaxel against prostate CSC-enriched cell populations.  Representative
FACS analysis shows a dose-dependent increase in the ratios of CD133high PPT2 (A) and PC3MM2 (B) cells 24 hours after
treatment with SBT-1214 and Ptx. Longer treatment (for 72 hours) with SBT-1214 (10 nM-10 µM) induced up to 65% cell death in
PPT2 cells (C) and up to 60% in PC3MM2 cells (D; lower line). In contrast, treatment with the same doses of Ptx did not suppress
proliferation of the tumorigenic prostate cancer cells (C, D; upper line). Cells were incubated with indicated drug concentrations, and
data was obtained with standard MMT assay based on three independent experiments with four repeats in each treatment group.
Values are the means±SD.
doi: 10.1371/journal.pone.0069884.g002
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passages, the majority of the PPT2 cells expressed cell surface
markers commonly used for the isolation of tumor-initiating
cells from different types of human cancer, including CD133,
CD44, CD44v6, EpCAM, CD166, CD49f, and presently, they
retain these features after more than 26 passages. The
CD133+ PPT2 cells possess up-regulated levels of the majority
of stem cell-related genes and several key transcription factors
that maintain embryonic stem cells in a pluripotent state,
including Sox-2, Oct-4 and c-Myc. The majority of these cells
express high levels of nestin and vimentin, the cytoskeletal
intermediate filament proteins characteristic for neural stem/
progenitor cells, which also suggests their immature stem-like
state. The involvement of SOX2 and OCT3/4 in prostate
metastasis was demonstrated by targeted knockdown of these
genes, which markedly suppressed the invasion of prostate
cancer cells in vitro [38]. Accumulating data also suggest that
Figure 3.  Treatment with SBT-1214 visualized the presence of large multinucleated cells, abolished the sphere-forming
capacity of survivor-cells and induced delayed cell death in CD133+ prostate cancer cells.  (A, B) Phase contrast
microphotographs show that a single treatment with 1 µM SBT-1214 for 48 hr induced death of the PPT2 and PC3MM2 cells with
enrichment of the large multinucleated cells (arrows). (C) Post-treatment loss of the sphere-forming capacity of survivor-cells
compared to untreated ones. Values are the means ±SD based on 3 independent repeats. (D) Profound death of treated PPT2 and
PC3MM2 cells during the next several days in culture.
doi: 10.1371/journal.pone.0069884.g003
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both vimentin and nestin may be the key players in the
transition from androgen-dependent to castration-resistant
metastatic prostate cancer [39,40]. Importantly, the PPT2 is the
first reported spontaneously immortalized prostate cancer cell
line established from a primary prostate tumor, which
possesses profound stemness characteristics, including up-
regulated stemness genes, high sphere-forming, clonogenic
and tumorigenic capacities and high resistance to
chemotherapeutic drugs. In contrast to the previously reported
spontaneously immortalized prostate cancer cell line Bob [41],
which expresses high levels of p53 and markers of early
differentiation—including K8, prostatic acid phosphatase and
prostate stem cell antigen—the PPT2 line is negative for p53
and p21. In contrast to the original tumor tissue, the CD133+
PPT2 cells did not express AR and PSA, which is in line with
other reports [21,42,43], and only a small fraction of the PPT2
cells express p63. A previous report has shown that all CD133+
cells isolated either from human telomerase reverse
transcriptase (hTERT)-immortalized primary nonmalignant, or
patient-derived malignant prostate epithelial cell lines retain
stem cell properties with a CD133+/CD44+/α2β1 + /34βE12 + / /
CK18 + /p63-/AR-/PSA− phenotype [19]. It is widely accepted
that, in contrast to normal prostate, malignant tumors do not
contain basal cells, or at least do not express their common
markers [44-47]. The functions of standard and variant CD44
isoforms remain unclear; however, their altered expression was
Figure 4.  Anti-tumor effects of SBT-1214 in vivo.  NOD/SCID mice were ectopically implanted with 3,000 of CD133+ PPT2 and
PC3MM2 cells on the flanks. Three weeks after injection, mice were treated with weekly i.v. injections of SBT-1214 (x4: 40, 20, 20,
20 mg/kg). This treatment modality induced dramatic reduction in tumor size in the majority of the PPT2- and PC3MM2-induced
tumors (A-D). Representative cases are shown on B and D. Values are the means ±SD; p≤0.0009 for PPT2-induced tumors (SBT-
treated versus untreated controls; n=6), and p≤0.0018 for PC3MM2-induced tumors (n=6). Histopathological analysis of the residual
tumors showed the presence of viable cells and accumulation of large multinucleated cells in 2 of 6 PPT2 tumors and 3 of 6
PC3MM2 tumors (representative H&E staining of untreated and SBT-1214-treated PPT2 tumor tissues is shown on E, F). Ex vivo
death of the drug-treated cells in culture (G). Control untreated tumor cells retained profound clonogenic and sphere-forming
capacities during serial passaging (H).
doi: 10.1371/journal.pone.0069884.g004
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demonstrated in several malignancies, including PrC [48]. In
particular, CD44v6 was previously suggested as an
independent indicator of poor prognosis in several cancer types
and as a biological marker for the degree of malignancy [49]. In
normal prostate glands, only rare basal and intermediate cells
showed CD44 and CD44v6 labeling [50].
The morphological manifestation of CSCs is not well studied,
partly because of the rarity of these cells and a lack of highly
specific markers. However, accumulating data demonstrate
that gigantic multinucleated cells, which are present in
relatively low numbers in malignant tissues and cell lines, and
can be enriched after treatment with standard anti-cancer
drugs [31,51], possibly represent a subpopulation of cancer
stem-like cells. Therefore, thorough analysis of such survivor
cells is necessary for the identification of signaling pathways
playing important roles in their biology and drug resistance. We
observed especially strong expression of nestin and vimentin in
such gigantic multinuclear treatment-survivor cells, which
suggests that the most drug-resistant cells are at the immature
state. Our data are in line with a recent report suggesting
nestin as a novel target for metastatic pancreatic cancer [52].
Higher expression of nestin and CD133 on circulating
melanoma cells was suggested as an index of poor prognosis
[53]. All of the above suggests that the PPT2 cells represent a
unique pre-clinical model for CSC-targeted drug development
and basic functional studies of prostate cancer development.
Microtubule stabilizers such as paclitaxel (Taxol) and
docetaxel can be initially effective in treating patients with
androgen-independent prostate cancer, but the cancer almost
invariably recurs in a more aggressive form [1,3,4]. Previously
we have shown that the new-generation taxoid SBT-1214
induced complete regression of drug-resistant colon tumor
xenografts in all surviving mice with unusually long-term tumor
growth delay (>167 days) [24]. Later, we have found that this
drug molecule induced significant down-regulation of multiple
stemness-related genes, including several key transcription
Figure 5.  Cytotoxic effects of the SBT-1214/CMC2.24 combination against prostate CD133+ cells.  (A, B) The CMC2.24 as a
single agent induced bi-phasic effects on prostate cancer cell proliferation: lower concentrations of it promoted proliferation,
whereas higher ones were cytotoxic. (C) In contrast to SBT-1214, treatment with CMC2.24 did not induce an increase in the ratio of
CD133+ cells (black dotted areas), but similarly to SBT-1214, increased expression of the differentiation marker pan-keratin (red
dotted areas) and shifted the entire cell population toward differentiation (areas with asterisks). A combination of the two agents
induced more significant cell death of the CD133+ PPT2 (D) and PC3MM2 (E) cells compared to each compound as a single agent.
Data were obtained with standard MMT assay (A, B, D, E). Values are the means ±SD of the three independent experiments with 4
repeats for each drug concentration.
doi: 10.1371/journal.pone.0069884.g005
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factors involved in the regulation of stem cells, cancer
development and progression [25]. Of note, it was shown that
docetaxel, which is the standard first-line therapy in metastatic
castration-resistant prostate cancer, can promote drug
resistance and de-differentiation (epithelial to mesenchymal
transition; EMT) of the DU-145 and PC-3 cells via TGF-beta
mechanism [54]. Cytotoxicity against prostate cancer cells can
be significantly reduced with a combination of Paclitaxel and
cyclopamine, a natural steroidal alkaloid that inhibits the
Hedgehog pathway [55]. The anti-cancer effects of another
natural phytochemical, curcumin (diferuloylmethane) were
recently demonstrated in a large number of studies. Of great
therapeutic interest, curcumin has been reported to induce the
anti-proliferative and apoptotic effects on drug-resistant stem-
like cells, and to improve the cytotoxic effects induced by
diverse chemotherapeutic drugs [56-59]. However, the poor
systemic bioavailability of curcumin and its high metabolic
instability limit its therapeutic efficacy. Therefore, it was of great
clinical significance to test the efficacy of CMC2.24, which has
no systemic toxicity and has much higher bioavailability and
activity compared to curcumin [29]. This prompted us to study
the effect of combining SBT-1214 with CMC2.24. We have
determined that a combination of the relatively low
concentrations of SBT-1214 (0.1-1 µM) with CMC2.24 (30-40
µM) induced up to 80-90% death of the highly tumorigenic and
highly drug-resistant prostate CD133+ cells maintained under
stemness-promoting culture conditions. In addition, the
significant up-regulation of the previously absent expression of
the pro-apoptotic proteins, p53 and p21 (“gene wake-up”
effect), and as a result, a dramatic increase in sensitivity to the
following treatment leads us to believe that this drug
combination can potentially reverse sensitivity to other anti-
cancer drugs. Similar effects were reported for curcumin, which
has been shown to activate p21 in breast [60], prostate [61]
Figure 6.  The SBT-1214/CMC2.24 combination induced suppression of the stem cell-relevant transcription factors in
CD133+ PPT2 cells.  (A) Multiple stem cell-relevant transcription factors are up-regulated in the CD133+ cell population compared
to their differentiated counterparts. (B) Down-regulation of the up-regulated transcription factors after treatment with 1 µM SBT-1214
and 10 µM CMC2.24 for 24 hr (PCR array assay; SABiosciences; PAHS 501). Western blot analysis confirmed significant down-
regulation of key pluripotency transcription factors, c-Myc and Sox-2 in CD133+ cells (C). Histon H1 was used as a loading control.
doi: 10.1371/journal.pone.0069884.g006
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and colon [62] cancer cell lines. In earlier studies, the reduced
expression of p21 in prostate cancer was associated with poor
survival outcome [63,64]. The fact that the SBT-1214/CMC2.24
combination exerted high direct cytotoxicity and down-
regulated the stemness state of highly tumorigenic and
clonogenic patient-derived CD133+ PPT2 cells is highly
promising, because it potentially can also be effective against
other patient-derived prostate CSC populations. Of interest, our
genomic analysis (which is out of the scope of the present
study) revealed that in addition to the lack of p53 and p21
expression, purified CD133+ PPT2 cells possess deletion of the
Y chromosome, which was previously shown to be associated
with the simultaneous inactivation of tumor suppressor genes
[65,66]. Numerical abnormalities detected in the X
chromosome in our CSC-enriched populations are also in line
with previous reports, which have shown that such changes are
present in 40% of prostate cancer cases [67,68] and are
associated with hormone-refractory prostate cancer [69,70]. In
general, loss of the Y chromosome and numerical
abnormalities of the X chromosome are frequent phenomena
observed in male patients with different cancer types [71], and
especially with prostate cancer [65-70].
In conclusion, our data indicate that the anti-cancer efficacy
of SBT-1214 in vitro and in vivo is most likely due to the down-
regulation of multiple stem cell-related genes in the tumorigenic
cell population (in addition to its known efficacy as a mitotic
poison against proliferating cancer cells). We also demonstrate
here that a combination of SBT-1214 with CMC2.24 exerts
more profound pleiotropic, pan-inhibitory effects on a large
number of stemness genes and transcription factors. In
particular, modulation of multiple stem cell-relevant
transcription factors and the pro-apoptotic p21 and p53 “gene
wake-up” mechanism can potentially reverse resistance of
CSCs to anti-cancer treatment and improve clinical outcome.
We believe that evaluation of the two proprietary drugs, which
exert pleiotropic CSC-targeted activities against primary
patient-derived, spontaneously immortalized, low passage,
highly tumorigenic and clonogenic prostate cancer cells with
CD133+/high/CD44 +/high/CD49f+/ high/EpCAM+/ high phenotype is
clinically relevant and has high potential as a novel anti-cancer
drug combination.
Figure 7.  The p53/p21 “gene-wake-up” induced by SBT-1214/CMC2.24 combination.  (A) Previously absent pro-apoptotic/
tumor suppressor proteins, p21 and p53 were induced by single treatment with SBT-1214/CMC2.24 combination for 24 hr in both
CD133+ and bulk PPT2 cells. Such “gene wake-up” led to significant increase in the sensitivity of the CD133+ cells to this drug
combination (B, C). Pre-treatment [SBT-1214 (1 µM) + CMC2.24 (10µM)]; second treatment [SBT-1214 (1 µM) + CMC2.24
variable]. Data were obtained with standard MMT assay.
doi: 10.1371/journal.pone.0069884.g007
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Methods
Prostate Tissues, Cells and Cultures
Human prostate needle biopsies were taken from otherwise
discarded surgical waste in accordance with the SBU IRB and
NIH requirements, via a research protocol that was approved
by Stony Brook University Committees on Research Involving
Human Subjects (CORIHS). Informed written consent was
obtained on all participants. The PPT2 prostate
adenocarcinoma cell line was established in March 2011 from
the stage pT2c pNX pMX prostate cancer patient as a part of
routine care for prostate cancer. Needle biopsies were
mechanically and enzymatically disaggregated into single cell
suspension at sterile conditions, rinsed with Hank’s balanced
salt solution and incubated for 1.5 hours at 37°C in serum-free
RPMI medium 1640 containing 200 units/ml Collagenases type
II and type IV (Sigma-Aldrich), 120 µg/ml penicillin and 100
µg/ml streptomycin. Cells were further disaggregated by
pipetting and serial filtration through cell dissociation sieves
(size 40 and 80 meshes; Sigma-Aldrich). Single cell
suspensions were placed on type-I collagen-coated dishes
(Biocoat; Becton Dickenson, Bedford, MA) in serum-free
Mesenchymal Stem Cell Growth Medium (MSCGM; Lonza) or
Stemline Pluripotent Culture Medium (SPCM; Sigma-Aldrich).
Fast adherent cells (within the following 15-20 min) were either
collected and placed on ultra-low-adherent (ULA) plates or
flasks (Corning) to induce floating 3D spheroids, or remained
on the type I collagen-coated dishes for further propagation.
Penicillin, streptomycin and TrypLE were obtained from
Invitrogen (Grand Island, NY, USA). The MSCGM and SPCM
were changed twice weekly. All experiments were performed
on primary prostate cancer patient-derived PPT2 cells and for
comparison, on the established highly metastatic derivative of
the androgen-independent PC-3 cell line, PC3MM2, originally
purchased from the M. D. Andersen Cancer Center, TX.
Isolation, Purification and Characterization of the
Tumor-Initiating Cells
To ensure more reliable isolation of CSCs, cells were labeled
with one or several markers conjugated with different
fluorescent dyes, including anti-human CD133/2-APC (clone
293C3; Miltenyi Biotec, CA, USA); CD166-PE (clone 105902;
R&D Systems, MN, USA); CD44-FITC (clone F10-44-2), CD44-
PE (clone F10-44-2; Invitrogen/Biosources, USA); CD44v6-
FITC (clone 2F10; R&D Systems, USA), EpCAM-FITC
(Biosource, CA, USA), Pan-Keratin (C11) -Alexa Fluor® 488
(Cell Signaling) and all the isotype controls (Chemicon).
Antibodies were diluted in buffer containing 5% BSA, 1mM
EDTA and 15-20% blocking reagent (Miltenyi Biotec) to inhibit
unspecific binding to non-target cells. After 15 min incubation at
4°C, stained cells were sorted and analyzed with
multiparametric flow cytometer BD FACSAria (Becton
Dickinson, CA). Alternatively, dissociated cells were
centrifuged at 950 g for 5 min at 4°C, rinsed with sterile MACS
buffer (Miltenyi Biotec, CA) and labeled with CD133 Abs
directly or indirectly conjugated with ferromagnetic beads
(Miltenyi Biotec, CA) as recommended by manufacturer.
Sphere Formation Assay
In order to obtain prostate cancer spheroids, MACS-CD133
and MACS-CD44 (Miltenyi Biotec, CA) or FACS sorted
CD133high/CD44high cells were seeded at low numbers on ULA
plates (1,000 cells per 6-well plate or 5-10,000 cells per 75 mm
flasks) in MSCGM or SPCM. For evaluation of the clonogenic/
sphere-forming capacity, cells were counted with Cellometer
Auto T4 (Nexcelom Bioscience LLC, MA), resuspended in 1:4
type I collagen/SPCM or 1:4 Matrigel/MSGM and known cell
numbers were plated on ULA plates. One week after initiation
plates were inspected for floating sphere growth and compact
well-shaped spheroids were counted. Spheroids were serially
passaged by gentle dissociation and mixing with a new
Matrigel/MSGM or type I collagen/SPCM, or reseeded on 48-
well plates for final count of 5-10 spheres per well for further
propagation and analysis.
Mice Tumor Xenografts
All experiments involving the use of animals were carried out
in strict accordance with the recommendations in the Guide for
the Care and Use of Laboratory Animals of the National
Institutes of Health, via a research protocol that was approved
by Stony Brook University Institutional Animal Care and Use
Committee (IACUC). NOD/SCID mice (Charles River
Laboratories International, Inc., MA) were maintained under
defined conditions at SBU animal facility. After sufficient
propagation, CD133+ cells were resuspended in 1:1 MSCGM/
Matrigel and injected to the flanks of 6 weeks old NOD/SCID
mice (3,000 cells per mice; subcutaneously). Tumor
development was monitored starting from the second week.
The primary tumor sizes were measured with a caliper on a
weekly basis and approximate tumor weights determined using
the formula 0.5ab2, where b is the smaller of the two
perpendicular diameters. All mice were terminated after fourth
week of treatment, if the tumor measured ~2 cm, or at the first
sign of suffering.
Ability to induce the round colonies (holoclones) was also
determined before and after drug treatment. Cells were
counted and plated on 48-well plates at a final count of 300
cells per well. One week after initiation, the plates were
inspected for colony growth and the number of colonies within
each well was quantified by phase contrast microscopy. After
drug treatment, one portion of cells which survived particular
treatment regimen was placed at 3D and adherent culture
conditions and analyzed. Another portion was used for analysis
of the drug-induced alterations in expression of the stem cell
markers with PCR array assay, western blotting and FACS.
Ability to induce the round colonies (holoclones) was also
determined before and after drug treatment. Cells were
counted and plated on 48-well plates at a final count of 300
cells per well. One week after initiation, the plates were
inspected for colony growth and the number of colonies within
each well was quantified by phase contrast microscopy. After
drug treatment, one portion of cells which survived particular
treatment regimen was placed at 3D and adherent culture
conditions and analyzed. Another portion was used for analysis
of the drug-induced alterations in expression of the stem cell
markers with PCR array assay, western blotting and FACS.
Prostate CSCs Inhibition with SBT-1214/CMC2.24
PLOS ONE | www.plosone.org 12 September 2013 | Volume 8 | Issue 9 | e69884
Drugs
Paclitaxel (Ptx; Taxol) was provided by Indena (Milan, Italy).
New-generation taxoid, SB-T-1214 was synthesized by Dr.
Ojima’s group (Stony Brook University, ICB&DD, NY, USA).
Chemically modified curcumin, CMC-2.24 was synthesized by
Dr. Johnson’s group (ChemMaster International, Inc., Stony
Brook, NY, USA). DMSO and MTT were purchased from Fisher
Scientific (Pittsburgh, PA, USA).
In vivo Cytotoxicity of SBT-1214
Animals were handled according to protocols that have been
approved by the Institutional Animal Care and Use committee
of the Stony Brook University. The staff of veterinarians
provided veterinary care. The SBT-1214 was administered
intravenously (40, 20, 20, 20 mg/kg weekly) to 6-weeks old
NOD/SCID mice. Treatment was started 2-3 weeks after
transplantation of the tumor cells, when tumor xenografts
reached ~100 mm3. Systemic toxicity in NOD/SCID mice was
closely monitored and evaluated by standard criteria (motor
activity, morbidity, appetite, posture and appearance). One
week after the last treatment, all residual tumors were
harvested and analyzed histopathologically and for ex vivo
clonogenic capacity. One part of each mouse tumor xenograft
was snap-frozen in embedding matrix (Lipshaw) and kept at
-80°C before immunohistochemical analysis at standard
conditions. Another portion of each harvested tumor was
mechanically and enzymatically disaggregated into single cell
suspension as previously described [18]. Ability to induce the
round colonies (holoclones) was also determined before and
after drug treatment. Cells were counted and plated on 48-well
plates at a final count of 300 cells per well. One week after
initiation, the plates were inspected for colony growth and the
number of colonies within each well was quantified by phase
contrast microscopy. After drug treatment, one portion of cells
which survived particular treatment regimen was placed at 3D
and adherent culture conditions and analyzed. Another portion
was used for analysis of the drug-induced alterations in
expression of the stem cell markers with PCR array assay,
western blotting and FACS.
In vitro Cytotoxicity
The CSC-specific cytotoxic effects were studied in two
different settings both of which are known to maintain/promote
stemness phenotype: adherent to type I collagen cultures and
3D cultures of floating spheroids [67-69]. The CD133high/
CD44high cells (1 × 103 cells/well) isolated either from PPT2 or
PC3MM2 cell lines were seeded onto the type I collagen-
coated 96-well plates, cultured in the MSCGM for 2 days, and
the treatment was initiated upon 90% confluency. Paclitaxel,
SBT-1214 and CMC2.24 were dissolved in sterile DMSO and
then serially diluted in MSCGM. For testing the SBT-1214/
CMC2.24 combination efficacy, the regular MSCGM was
replaced with treatment medium containing SBT-1214 or Ptx at
selected concentration range (from 10 nM to 10 µM) with 30
µM CMC2.24. Treatment medium was removed 24, 48 or 72 hr
later, followed by return to the MSCGM. Cell death was
analyzed on adherent type I collagen cell cultures with the MTT
assay [MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] as recommended by
manufacturer (Invitrogen). Spheroids were cultured and treated
on ULA plates.
PCR Array Assay
Stem cell-specific transcription factors gene expression
profiles were studied with the PCR Array assay
(SABiosciences, CA; PAHS-501) in accordance with the
manufacturer’s recommendations. Briefly, total RNA was
isolated from different cell populations or whole floating
spheroids using PARIS kit (Ambion). Up to 1 µg of total RNA
was treated with DNase and cDNA was prepared using RT2
First Strand kit. For each analysis, pairs of the test and control
cDNA samples were mixed with RT2 qPCR Master mix and
distributed across the PCR array 96-well plates, each of which
contained 84 stem cell-related probes and control
housekeeping genes. After cycling with real-time PCR,
obtained amplification data (fold-changes in Ct values of all the
genes) was analyzed with the SABiosciences software.
Western Blot Analysis
Cells were lysed using Active Motif Nuclear Co-ip kit
according to manufacturer’s protocol. 20µg of enriched nuclear
and cytoplasmic extracts was subjected to electrophoresis in
10% polyacrylamide gel. The proteins were then transferred to
a nitrocellulose membrane and developed with appropriate
antibodies. Mouse monoclonal antibody against Histone H1
(05-457) and GAPDH (MAB374) were purchased from Millipore
and mouse monoclonal antibody against p21 was purchased
from BD Pharmingen (556431). Rabbit antibody against p53
was purchased from Santa Cruz Biotechnology (sc-6243).
Rabbit antibodies against Sox2 (2748), C-Myc (5605), and
Oct4 (2750) were purchased from Cell Signaling.
Statistical Analysis
The dose-response cytotoxicity of SBT-1214, CMC2.24/and
their combination was evaluated by standard MTT assay (all of
the in vitro experiments were repeated at least three times and
each measurement for the MMT assay was performed in 4
repeats). The dose-response points were plotted as a
percentage of the untreated control, the absorbance of which
was considered as 100%. Data were expressed as means ±
SD for each drug concentration. The in vivo responses to drug
treatment were evaluated as changes in tumor volume of drug-
treated versus untreated control xenografts induced by
particular type of cells. Data were expressed as means ± SD
for control and drug treated tumors. The statistical significance
of differences was determined using Student’s t-test. The
parameters used were the two-tailed distribution and the paired
test.
P<0.05 was considered statistically significant.
Acknowledgements
We gratefully acknowledge the expert performance of
proteomic analyses by Dr. Alexander Ivanov (Harvard
proteomics Resource). We acknowledge the expert
professional assistance of Todd Rueb with flow cytometry and
Prostate CSCs Inhibition with SBT-1214/CMC2.24
PLOS ONE | www.plosone.org 13 September 2013 | Volume 8 | Issue 9 | e69884
Stephanie Burke with histopathological evaluation (SBU). We
thank Dr. Eric Lifrak (Department of Pathology, Long Beach VA
Healthcare System, University of California Irvine Medical
School) for productive discussions. The authors gratefully
thank the irreplaceable help of Ekaterina Botchkina (MIT,
Cambridge, MA) and Michael Stynes (NYU, NY) with the
editing of this manuscript.
Author Contributions
Conceived and designed the experiments: ESZ RP RHR RB
ABB FJ LMG YZ KRS IO GIB. Performed the experiments:
ESZ RHR ABB YZ KRS GIB. Analyzed the data: ESZ RP RHR
RB ABB FJ LMG YZ KRS IO GIB. Contributed reagents/
materials/analysis tools: RP RP RB ABB FJ LMG YZ KRS IO
GIB. Wrote the manuscript: GIB.
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011)
Global Cancer Statistics. CA Cancer J Clin 61: 69-90. doi:10.3322/
caac.20107. PubMed: 21296855.
2. van Brussel JP, Mickisch GH (2003) Multidrug resistance in prostate
cancer. Onkologie 26: 175-181. doi:10.1159/000071510. PubMed:
12771527.
3. Zivi A, Massard C, De-Bono J (2010) Changing therapeutic paradigms
in castrate-resistant prostate cancer. Clin Genitourin Cancer 8: 17-22.
doi:10.3816/CGC.2010.n.003. PubMed: 21208851.
4. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells,
cancer, and cancer stem cells. Nature 414: 105-111. doi:
10.1038/35102167. PubMed: 11689955.
5. Nautiyal J, Du J, Yu Y, Kanwar SS, Levi E, Majumdar AP (2012) EGFR
regulation of colon cancer stem-like cells during aging and in response
to the colonic carcinogen dimethylhydrazine. Am J Physiol Gastrointest
Liver Physiol 302(7): G655-G663. doi:10.1152/ajpgi.00323.2011.
PubMed: 22281474.
6. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z et al. (2006) Stem cell-
like glioma cells promote tumor angiogenesis through vascular
endothelial growth factor. Cancer Res 66: 7843-7848. doi:
10.1158/0008-5472.CAN-06-1010. PubMed: 16912155.
7. Dirks PB (2006) Cancer: Stem cells and brain tumours. Nature 444:
687-688. doi:10.1038/444687a. PubMed: 17151644.
8. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L et al.
(2007) Colon cancer stem cells dictate tumor growth and resist cell
death by production of interleukin-4. Cell Stem Cell 1: 389-402. doi:
10.1016/j.stem.2007.08.001. PubMed: 18371377.
9. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen
JM (2007) WNT/beta-catenin mediates radiation resistance of mouse
mammary progenitor cells. Proc Natl Acad Sci U S A 104: 618-623. doi:
10.1073/pnas.0606599104. PubMed: 17202265.
10. Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J et al. (2008)
Colorectal cancer stem cells are enriched in xenogeneic tumors
following chemotherapy. PLOS ONE 3: e2428. doi:10.1371/
journal.pone.0002428. PubMed: 18560594.
11. Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A et al. (2009)
Highly tumorigenic lung cancer CD133+ cells display stem-like features
and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 106:
162881-116286. PubMed: 19805294.
12. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT et
al. (2009) PTEN/PI3K/Akt pathway regulates the side population
phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell
Stem Cell 4: 226-235. doi:10.1016/j.stem.2009.01.007. PubMed:
19265662.
13. Mimeault M, Batra SK SK (2010) New advances on critical implications
of tumor- and metastasis-initiating cells in cancer progression,
treatment resistance and disease recurrence. Histol Histopathol 25:
1057-1073. PubMed: 20552555.
14. Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, Patel
C, Orina JN, Eliseeva TA, Singal V, Padmanabhan R, Davidson B,
Ganapathi R, Sood AK, Rueda BR, Ambudkar SV, Gottesman MM14
Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ et al (2011)
Redefining the relevance of established cancer cell lines to the study of
mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci
U S A 108: 18708-18713. doi:10.1073/pnas.1111840108. PubMed:
22068913.
15. Hutchinson L, Kirk Rebecca (2011) High drug attrition rates – where
are we going wrong? Nat Rev Clin Oncol 8: 189-190. doi:10.1038/
nrclinonc.2011.34. PubMed: 21448176.
16. Peehl DM (2004) Are primary cultures realistic models of prostate
cancer? J Cell Biochem 91: 185–195. doi:10.1002/jcb.10691. PubMed:
14689590.
17. Patrawala L, Calhoun T, Schneider-Broussardected ou J, Claypool K,
Tang DG (2005) Side population is enriched in tumorigenic, stem-like
cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly
tumorigenic. Cancer Res 65: 6207–6219
18. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW et al. (2007)
Distinct Populations of Cancer Stem Cells Determine Tumor Growth
and Metastatic Activity in Human Pancreatic Cancer. Cell Stem Cell 1:
313-323. doi:10.1016/j.stem.2007.06.002. PubMed: 18371365.
19. Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, Sesterhenn IA,
McLeod DG, Srivastava S, Rhim JS19 Miki J, Furusato B, Li H, Gu Y,
Takahashi H et al (2007) Identification of putative stem cell markers,
CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and
malignant tumor-derived human prostate epithelial cell lines and in
prostate cancer specimens. Cancer Res 67(7): 3153-3161. doi:
10.1158/0008-5472.CAN-06-4429. PubMed: 17409422.
20. Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA et al.
(2009) Invasive prostate cancer cells are tumor initiating cells that have
a stem cell-like genomic signature. Clin Exp Metastasis 26(5): 433-446.
doi:10.1007/s10585-009-9242-2. PubMed: 19221883.
21. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON (2010)
Identification of a cell of origin for human prostate cancer. Science 329:
568–571. doi:10.1126/science.1189992. PubMed: 20671189.
22. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H et al.
(2009) A luminal epithelial stem cell that is a cell of origin for prostate
cancer. Nature 461: 495–500. doi:10.1038/nature08361. PubMed:
19741607.
23. Guo C, Liu H, Zhang BH, Cadaneanu RM, Mayle AM et al. (2012)
Epcam, CD44, and CD49f Distinguish Sphere-Forming Human
Prostate Basal Cells from a Subpopulation with Predominant Tubule
Initiation Capability. PLOS ONE 7(4): e34219. doi:10.1371/
journal.pone.0034219. PubMed: 22514625.
24. Kuznetsova L, Chen J, Sun L, Wu X, Pepe A et al. (2006) Syntheses
and evaluation of novel fatty acid-second-generation taxoid conjugates
as promising anticancer agents. Bioorg Med Chem Lett 16: 974-977.
doi:10.1016/j.bmcl.2005.10.089. PubMed: 16298526.
25. Botchkina GI, Zuniga ES, Das M, Wang Y, Wang H et al. (2010) New-
generation taxoid SB-T-1214 inhibits stem cell-related gene expression
in 3D cancer spheriods induced by purified colon tumor-initiating cells.
Mol Cancer 9: 192-204. doi:10.1186/1476-4598-9-192. PubMed:
20630067.
26. Mimeault M, Batra SK (2011) Potential applications of curcumin and its
novel synthetic analogs and nanotechnology-based formulations in
cancer prevention and therapy. Chin Med 6: 31. doi:
10.1186/1749-8546-6-31. PubMed: 21859497.
27. Shankar S, Srivastava RK (2007) Involvement of Bcl-2 family members,
phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin
(diferulolylmethane)-induced apoptosis in prostate cancer. Int J Oncol
30: 905-918. PubMed: 17332930.
28. Piantino CB, Salvadori FA, Ayres PP, Kato RB, Srougi V et al. (2009)
An evaluation of the anti-neoplastic activity of curcumin in prostate
cancer cell lines. Int Braz J Urol 35: 354-360. doi:10.1590/
S1677-55382009000300012. PubMed: 19538771.
29. Zhang Y, Gu Y, Lee H-M, Hambardjieva K, Vranková L et al. (2012)
Design, synthesis and biological activity of new polyenolic inhibitors of
matrix metalloproteinases: a focus on chemically-modified curcumins.
Prostate CSCs Inhibition with SBT-1214/CMC2.24
PLOS ONE | www.plosone.org 14 September 2013 | Volume 8 | Issue 9 | e69884
Curr Med Chem 19(25): 4348-4358. doi:
10.2174/092986712802884295. PubMed: 22830350.
30. Rowehl RH, Crawford H, Dufour A, Leyfman Y, Ju J, Botchkina GI
(2008) Genomic Analysis of Prostate Cancer Stem Cells Isolated from
Highly Metastatic Cell Line. Cancer Genomics Proteomics 5: 301-309.
PubMed: 19287071.
31. Botchkina IL, Rowehl RA, Rivadeneira DE, Karpeh MSJ, Crawford H et
al. (2009) Phenotypic Subpopulations of Metastatic Colon Cancer Stem
Cells. Cancer Genomics Proteomics 6: 19-30. PubMed: 19451087.
32. 32; Botchkina GI, Ojima I (2011) Prostate and colon cancer stem cells
as a target for anti- cancer drug development. In Cancer Stem Cells
Theories and Practice. S Shostak. Intech: 135-154.
33. Birnie R, Bryce SD, Roome C, Dussupt V, Droop A et al. (2008) Gene
expression profiling of human prostate cancer stem cells reveals a pro-
inflammatory phenotype and the importance of extracellular matrix
interactions. Genome Biol 9: R83. doi:10.1186/gb-2008-9-5-r83.
PubMed: 18492237.
34. Kelly K, Yin JJ (2008) Prostate cancer and metastasis initiating stem
cells. Cell Res 18: 528-537. doi:10.1038/cr.2008.50. PubMed:
18414448.
35. Bisson I, Prowse DM (2009) WNT signaling regulates self-renewal and
differentiation of prostate cancer cells with stem cell characteristics.
Cell Res 19: 683-697. doi:10.1038/cr.2009.43. PubMed: 19365403.
36. Verras M, Sun Z (2006) Roles and regulation of Wnt signaling and
beta-catenin in prostate cancer. Cancer Lett 237: 22-32. doi:10.1016/
j.canlet.2005.06.004. PubMed: 16023783.
37. Hall CL, Zhang H, Baile S, Ljungman M, Kuhstoss S, Keller ET (2010)
p21CIP-1/WAF-1 induction is required to inhibit prostate cancer growth
elicited by deficient expression of the Wnt inhibitor Dickkopf-1. Cancer
Res 70: 9916-9926. doi:10.1158/0008-5472.CAN-10-0440. PubMed:
21098705.
38. Bae K-M, Parker NN, Dai Y, Vieweg J, Siemann DW (2011) E-cadherin
plasticity in prostate cancer stem cell invasion. Am J Cancer Res 1:
71-84. PubMed: 21968440.
39. Kleeberger W, Bova GS, Nielsen ME, Herawi M, Chuang A-Y et al.
(2007) Roles for the Stem Cell–Associated Intermediate Filament
Nestin in Prostate Cancer Migration and Metastasis. Cancer Res 67:
9199-9206. doi:10.1158/0008-5472.CAN-07-0806. PubMed: 17909025.
40. Zhao Y, Yan Q, Long X, Chen X, Wang Y (2008) Vimentin affects the
mobility and invasiveness of prostate cancer cells. Cell Biochem Funct
26: 571-577. doi:10.1002/cbf.1478. PubMed: 18464297.
41. Attard G, Rizzo S, Ledaki I, Clark J, Reid AH et al. (2009) A novel,
spontaneously immortalized, human prostate cancer cell line, Bob,
offers a unique model for pre-clinical prostate cancer studies. Prostate
69(14): 1507-1520. doi:10.1002/pros.20997. PubMed: 19544327.
42. Uzgare AR, Xu Y, Isaacs JT (2004) In vitro culturing and characteristics
of transit amplifying epithelial cells from human prostate tissue. J Cell
Biochem 91: 196–205. doi:10.1002/jcb.10764. PubMed: 14689591.
43. Peehl DM (2005) Primary cell cultures as models of prostate cancer
development. Endocr Relat Cancer 12: 19–47. doi:10.1677/erc.
1.00795. PubMed: 15788637.
44. Signoretti S, Waltregny D, Dilks J et al. (2000) p63 is a prostate basal
cell marker and is required for prostate development. Am J Pathol 157:
1769–1775. doi:10.1016/S0002-9440(10)64814-6. PubMed: 11106548.
45. Di Como CJ, Urist MJ, Babayan I et al. (2002) p63 expression profiles
in human normal and tumor tissues. Clin Cancer Res 8: 494–501.
PubMed: 11839669.
46. Oliai BR, Kahane H, Epstein JI (2002) Can basal cells be seen in
adenocarcinoma of the prostate?: an immunohistochemical study using
high molecular weight cytokeratin (clone 34βE12) antibody. Am J Surg
Pathol 26: 1151–1160. doi:10.1097/00000478-200209000-00005.
PubMed: 12218571.
47. Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA (2002)
Comparison of the basal cell-specific markers, 34βE12 and p63, in the
diagnosis of prostate cancer. Am J Surg Pathol 26: 1161–1168. doi:
10.1097/00000478-200209000-00006. PubMed: 12218572.
48. Aaltomaa S, Lipponen P, Ala-Opas M, Kosma V-M (2001)
Downregulation of CD44 Expression and Prognostic Value of CD44
Standard and Variant v3 and v6 Isoforms in Prostate Cancer. Eur Urol
39: 138–144. doi:10.1159/000052428. PubMed: 11223672.
49. Hirata T, Fukuse T, Naiki H, Hitomi S, Wada H (1998) Expression of
CD44 Variant Exon 6 in Stage I Non-Small Cell Lung Carcinoma as a
Prognostic Factor. Cancer Res 58: 1108–1110. PubMed: 9515789.
50. Alam TN, O’Hare MJ, Laczkó I, Freeman A, Al-Beidh F et al. (2004)
Differential expression of CD44 during human prostate epithelial cell
differentiation. J Histochem Cytochem 52: 1083-1090. doi:10.1369/jhc.
4A6256.2004. PubMed: 15258184.
51. Weihua Z, Lin Q, Ramoth AJ, Fan D, Fidler IJ (2011) Formation of solid
tumors by a single multinucleated cancer cell. Cancer 117: 4092-4099.
doi:10.1002/cncr.26021. PubMed: 21365635.
52. Matsuda Y, Naito Z, Kawahara K, Nakazawa N, Korc M, Ishiwata T
(2011) Nestin is a novel target for suppressing pancreatic cancer cell
migration, invasion and metastasis. Cancer Biol Ther 11: 512-523. doi:
10.4161/cbt.11.5.14673. PubMed: 21258211.
53. Fusi A, Reichelt U, Busse A, Ochsenreither S, Rietz A et al. (2011)
Expression of the stem cell markers nestin and CD133 on circulating
melanoma cells. J Invest Dermatol 131: 487-494. doi:10.1038/jid.
2010.285. PubMed: 20882037.
54. Marín-Aguilera M, Codony-Servat J, Kalko SG, Fernández PL,
Bermudo R et al. (2012) Identification of docetaxel resistance genes in
castration-resistant prostate cancer. Mol Cancer Ther 11(2): 329-339.
doi:10.1158/1535-7163.MCT-11-0289. PubMed: 22027694.
55. Singh S, Chitkara D, Mehrazin R, Behrman SW, Wake RW, Mahato RI
(2012) Chemoresistance in Prostate Cancer Cells Is Regulated by
miRNAs and Hedgehog Pathway. PLOS ONE 7: e40021. doi:10.1371/
journal.pone.0040021. PubMed: 22768203.
56. Yu Y, Kanwar SS, Patel BB, Nautiyal J, Sarkar FH, Majumdar AP
(2009) Elimination of Colon Cancer Stem-Like Cells by the
Combination of Curcumin and FOLFOX. Transl Oncol 2: 321-328.
PubMed: 19956394.
57. Fong D, Yeh A, Naftalovich R, Choi TH, Chan MM (2010) Curcumin
inhibits the side population (SP) phenotype of the rat C6 glioma cell
line: towards targeting of cancer stem cells with phytochemicals.
Cancer Lett 293: 65-72. doi:10.1016/j.canlet.2009.12.018. PubMed:
20089354.
58. Kakarala M, Brenner DE, Korkaya H, Cheng C, Tazi K et al. (2010)
Targeting breast stem cells with the cancer preventive compounds
curcumin and piperine. Breast Cancer Res Treat 122: 777-785. doi:
10.1007/s10549-009-0612-x. PubMed: 19898931.
59. Bao B, Ali S, Kong D, Sarkar SH, Wang Z et al. (2011) Anti-tumor
activity of a novel compound-CDF is mediated by regulating miR-21,
miR-200, and PTEN in pancreatic cancer. PLOS ONE 6: e17850. doi:
10.1371/journal.pone.0017850. PubMed: 21408027.
60. Aggarwal BB, Sundaram C, Malani N, Ichikawa H (2007) Curcumin: the
Indian solid gold. Adv Exp Med Biol 595: 1-75. doi:
10.1007/978-0-387-46401-5_1. PubMed: 17569205.
61. Hour TC, Chen J, Huang CY, Guan JY, Lu SH, Pu YS (2002) Curcumin
enhances cytotoxicity of chemotherapeutic agents in prostate cancer
cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and
suppressing NF-kappaB activation. Prostate 51: 211-218. doi:10.1002/
pros.10089. PubMed: 11967955.
62. Su CC, Lin JG, Li TM, Chung JG, Yang JS et al. (2006) Curcumin-
induced apoptosis of human colon cancer colo 205 cells through the
production of ROS, Ca2+ and the activation of caspase-3. Anticancer
Res 26: 4379-4389. PubMed: 17201158.
63. Matsushima H, Sasaki T, Goto T, Hosaka Y, Homma Y et al. (1998)
Immunohistochemical study of p21WAF1 and p53 proteins in prostatic
cancer and their prognostic significance. Hum Pathol 29: 778-783. doi:
10.1016/S0046-8177(98)90445-2. PubMed: 9712417.
64. Cheng L, Lloyd RV, Weaver AL, Pisansky TM, Cheville JC et al. (2000)
The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with
survival in patients treated by salvage prostatectomy after radiation
therapy. Clin Cancer Res 6: 1896-1899. PubMed: 10815913.
65. Perinchery G, Sasaki M, Angan A, Kumar V, Carroll P, Dahiya R (2000)
Deletion of Y-chromosome specific genes in human prostate cancer. J
Urol 163: 1339-1342. doi:10.1016/S0022-5347(05)67774-9. PubMed:
10737540.
66. Vijayakumar S, Garcia D, Hensel CH, Banerjee M, Bracht T et al.
(2005) The human Y chromosome suppresses the tumorigenicity of
PC-3, a human prostate cancer cell line, in athymic nude mice. Genes
Chromosomes Cancer 44: 365-372. doi:10.1002/gcc.20250. PubMed:
16080199.
67. Baretton GB, Valina C, Vogt T, Schneiderbanger K, Diebold J, Löhrs U
(1994) Interphase cytogenetic analysis of prostatic carcinomas by use
of nonisotopic in situ hybridization. Cancer Res 54: 4472-4480.
PubMed: 8044798.
68. Miyoshi Y, Uemura H, Fujinami K, Mikata K, Harada M et al. (2000)
Fluorescence in situ hybridization evaluation of c-myc and androgen
receptor gene amplification and chromosomal anomalies in prostate
cancer in Japanese patients. Prostate 43: 225-232. doi:10.1002/
(SICI)1097-0045(20000515)43:3. PubMed: 10797498.
69. Koivisto P, Hyytinen E, Palmberg C, Tammela T, Visakorpi T et al.
(1995) Analysis of genetic changes underlying local recurrence of
prostate carcinoma during androgen deprivation therapy. Am J Pathol
147: 1608-1614. PubMed: 7495286.
Prostate CSCs Inhibition with SBT-1214/CMC2.24
PLOS ONE | www.plosone.org 15 September 2013 | Volume 8 | Issue 9 | e69884
70. Luo JH, Yu YP (2003) Genetic factors underlying prostate cancer.
Expert Rev Mol Med 5: 1-26. PubMed: 14585168.
71. Nieländer I, Martín-Subero JI, Wagner F, Baudis M, Gesk S et al.
(2008) Recurrent loss of the Y chromosome and homozygous deletions
within the pseudo-autosomal region 1: association with male
predominance in mantle cell lymphoma. Haematol 93: 949-950. doi:
10.3324/haematol.12656.
Prostate CSCs Inhibition with SBT-1214/CMC2.24
PLOS ONE | www.plosone.org 16 September 2013 | Volume 8 | Issue 9 | e69884
